Feature | July 02, 2014 | Melinda Taschetta-Millane

Trends from SNMMI 2014

The Society of Nuclear Medicine and Molecular Imaging (SNMMI) recently held its annual meeting in St. Louis. It provided an in-depth review of molecular imaging technologies, clinical applications, and translational and advanced research topics for molecular imaging professionals — nuclear medicine physicians, scientists, radiologists, cardiologists, pharmacists, technologists, researchers, and others involved and interested in nuclear medicine and molecular imaging and therapy.

On the show floor, several vendors introduced new PET/CT systems for the market. 

Among them was Philips’ Vereos, which is the first on the market to offer digital PET detectors, and offers greater image clarity over traditional analog photomultipliers. 

Toshiba announced the release of its Celesteion system. It currently is pending 510(k) clearance from the U.S. Food and Drug Administration (FDA), and combines high-performance PET and CT for all radiation and oncology imaging needs, including tumor detection, treatment evaluation and CT simulation.

In addition, GE Healthcare introduced its Discovery IQ PET/CT system. It enables both high image quality and intelligent quantitation. It is pending 510(k) clearance from the FDA and not available for sale in the United States. 

You can learn more about the trends and technology showcased at SNMMI 2014 by viewing the videos Editor’s Choice of Most Innovative Technology at SNMMI 2014” and “SNMMI: Trends and New Technology in Nuclear Imaging.” 

Several interesting studies came out of the show, as well, and covered a vast spectrum of topics, including:

• Antibody-based molecular imaging agent hones in on newly targeted cell receptor that 

hints at more aggressive breast cancers and potential therapy;

• Molecular neuroimaging shows a strong association between a sleep disorder and the development of progressive brain diseases such as Parkinson’s;

• Study finds the newest hybrid cardiac molecular imaging system highly effective for the detection of coronary arterial disease;

• Molecular imaging study suggests late-life depression and beta-amyloid plaque in the brain could tip-off hastened development of deadly dementia;

• Researchers can now use radioluminescence to examine the characteristics of single, unconnected cells, and the result is a fascinating picture of diversity among cells previously assumed to behave the same; and

• Wide range of molecular imaging modalities is at researchers’ fingertips with a hybrid device dedicated for early-stage clinical trials.

As always, you can read more about these innovative studies, as well as other industry news, at www.itnonline.com

Related Content

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows).

In scans of a 62-yr-old man with Gleason 4+3 PCa treated with radical prostatectomy, with rising PSA level (1.32) and PSA doubling time of 3.7 months, 64CuCl2-PET/CT images revealed 2 positive small left iliac lymph nodes (A,C), whereas 18F-Choline PET/CT (B,D) was negative (arrows). Image courtesy of A Piccardo et al., Galliera Hospital, Genoa, Italy.

News | Prostate Cancer | March 07, 2018
An Italian study featured in the March i
Axumin PET Agent Added to NCCN Guidelines for Suspected Recurrent Prostate Cancer
News | PET Imaging | February 21, 2018
Blue Earth Diagnostics announced that Axumin (fluciclovine F 18) injection has been added to the National Comprehensive...
A Tc99m SPECT cardiac exam showing myocardial perfusion in the heart.

Technetium-99m is primarily used for the detection of cancer and to assess perfusion defects in the heart caused by heart attacks or other conditions.

Feature | Radiopharmaceuticals and Tracers | February 08, 2018 | Dave Fornell
February 8, 2018 — The U.S.
PSMA PET-CT Clearly Differentiates Prostate Cancer from Benign Tissue

68Ga-PSMA PET/CT images showing multifocal PCA in peripheral zone with GS of 5 1 5 5 10. (A and C) Axial PET images. (B and D) Fused PET/CT images. SUVmax of lesion in B was 84.3 and that of lesion in D was 5.7. IRS was 3, and 80% of cells were stained. Credit: Senior author V Prasad, Charité Universitätsmedizin Berlin, Berlin, Germany.

News | PET-CT | February 05, 2018
February 5, 2018 — Using nuclear medicine...
Novel PET Tracer Clearly Identifies and Tracks Bacterial Lung Infection

Representative PET/CT images of 18F-FDS and 18F-FDG in inflamed mice. Mice were inoculated with dead K. pneumoniae (10^8 CFU/mL). Imaging was performed for days 1, 2, 3 and 4 using 18F-FDG and 18F-FDS. CT images showed clear inflammation on day 2 and day 3 with corresponding high 18F-FDG uptake on PET. No significant uptake of 18F-FDS was detected for any of those 4 days. Credit: J Li et al., University of Louisville School of Medicine, Louisville, Ky.

News | PET-CT | January 22, 2018
January 22, 2018 — Researchers at the University of Louisville, Kentucky, have demonstrated that a new...
Netherlands Cancer Institute Exploring Molecular Imaging Technology for Prostate Cancer Surgery
News | Molecular Imaging | October 26, 2017
The Netherlands Cancer Institute (NKI) announced it has received funding from the Dutch Cancer Society (KWF...
SNMMI Publishes New FDG PET/CT Appropriate Use Criteria
News | PET-CT | October 25, 2017
The Society of Nuclear Medicine and Molecular Imaging (SNMMI) has published appropriate use criteria (AUC) for FDG PET/...
Majority of Recurrent Prostate Cancer Patients' Treatment Plan Changed Following Fluciclovine 18F PET/CT
News | Prostate Cancer | October 04, 2017
Blue Earth Diagnostics recently announced the results of a pre-planned interim analysis from an investigational...
Toshiba Highlights Latest CT Advancements at RSNA 2017
News | Computed Tomography (CT) | September 18, 2017
Toshiba Medical announced that it will display several new enhancements to its existing computed tomography (CT)...
Double Targeting Ligands to Identify and Treat Prostate Cancer

The mice were imaged with small-animal PET/CT using 124I-RPS-027 (7.4 MBq [200 μCi]). Credit: JM Kelly et al., Department of Radiology, Weill Cornell Medicine, New York, NY

News | Prostate Cancer | September 14, 2017
Researchers have demonstrated a new, effective way to precisely identify and localize prostate cancer tumors while...
Overlay Init